BJI

Brown Jordan Inc. Announces Gene J. Moriarty to Step Down as President and Chief Executive Officer

Retrieved on: 
Thursday, May 11, 2023
Interior Design, Retail, Home Goods, Residential Building & Real Estate, Commercial Building & Real Estate, Specialty, Construction & Property, Littlejohn & Co., Global recession, Great Recession, Growth, BJI, Gene, Faber-Castell, Littlejohn

Brown Jordan Inc. (“Brown Jordan” or “BJI”) announced today that after 18 years of distinguished service, Gene J. Moriarty will be retiring later this year as president and chief executive officer.

Key Points: 
  • Brown Jordan Inc. (“Brown Jordan” or “BJI”) announced today that after 18 years of distinguished service, Gene J. Moriarty will be retiring later this year as president and chief executive officer.
  • “On behalf of the Board, I want to thank Gene for his countless contributions to Brown Jordan, which span nearly two decades,” said Michael Klein, chief executive officer of Littlejohn.
  • Mr. Moriarty helmed the successful integration and growth of two key acquisitions: Tropitone Furniture in 2014 and Castelle in 2019.
  • “Leading Brown Jordan for the past 18 years has been the honor of my career,” said Gene Moriarty.

Acute Bacterial Skin and Skin Structure Infections Pipeline Landscape Report 2022: Comprehensive Insights About 15+ Companies and 15+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 25, 2022
Health, Other Health, GSK, MOA, DNA, Gepotidacin, QIDP, Șaeș, II, Food, US Foods, FIH, Mergers and acquisitions, Infection, Boston University, Eurasian Economic Union, DNA gyrase, Marketing, Antibiotic sensitivity testing, Research, FDA, Partnership, Epis, Technology, Economic union, Drug of last resort, MDR, NDA, Therapy, Airports Company South Africa, Acquisition, ABSSSI, BJI, Pharmaceutical industry, Antibiotics, Vaccine, Acute, Basel

This "Acute Bacterial Skin and Skin Structure Infections - Pipeline Insight, 2022" report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Acute Bacterial Skin and Skin Structure Infections pipeline landscape.

Key Points: 
  • This "Acute Bacterial Skin and Skin Structure Infections - Pipeline Insight, 2022" report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Acute Bacterial Skin and Skin Structure Infections pipeline landscape.
  • A detailed picture of the Acute Bacterial Skin and Skin Structure Infections pipeline landscape is provided which includes the disease overview and Acute Bacterial Skin and Skin Structure Infections treatment guidelines.
  • The assessment part of the report embraces, in depth Acute Bacterial Skin and Skin Structure Infections commercial assessment and clinical assessment of the pipeline products under development.
  • Acute Bacterial Skin and Skin Structure Infections: Therapeutic Assessment
    This segment of the report provides insights about the different Acute Bacterial Skin and Skin Structure Infections drugs segregated based on following parameters that define the scope of the report, such as:
    There are approx.